Thermo Fisher Scientific reports record performance in Q3 2010

Thermo Fisher Scientific has published its financial report for the third quarter of 2010, during which the company experienced a record-breaking fiscal performance.

The science firm accumulated $2.7 billion (1.7 billion pounds) in revenues for the three-month period, a year-on-year increase of six percent, with acquisitions accounting for three percent of the growth.

Its adjusted earnings per share total was up by 15 percent, representing its best-ever figure for the third quarter, while income and margins also saw annual increases.

Marc Casper, president and chief executive officer of Thermo Fisher Scientific, stated that the business' expansion is being driven by product launches such as its new immunosuppressant drug analysis range, as well as investment in acquisitions such as Fermentas.

He added: "We remain confident that we will continue our track record of creating shareholder value through strong operating and financial performance, as well as disciplined capital deployment."

Last month, the firm created a new scientific advisory board in order to foster an improved dialogue with the healthcare sector.